Cargando…

PB2475: SECRETED FACTORS FROM BONE MARROW-DERIVED FIBROBLASTS PROTECT AML CELLS AGAINST APOPTOSIS MEDIATED BY A NOVEL CDK/MCL-1 INHIBITOR VIA STAT3/MCL-1 SIGNALLING

Detalles Bibliográficos
Autores principales:	Miari, Katerina, Guzman, Monica, Wheadon, Helen, Williams, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429310/ http://dx.doi.org/10.1097/01.HS9.0000976604.57461.cc

Ejemplares similares

PB1793: MCL-1 INHIBITION AFFECTS LIPIDOME WHICH MAY BE LINKED TO TUMOR IMMUNITY AND CANCER-RELATED INFLAMMATION IN ACUTE MYELOID LEUKEMIA
por: Yandim, Melis Kartal, et al.
Publicado: (2023)

Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML
por: O’ Reilly, Eimear, et al.
Publicado: (2018)

DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex
por: Nakajima, Wataru, et al.
Publicado: (2016)

The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010)

Mcl-1 Ubiquitination and Destruction
por: Inuzuka, Hiroyuki, et al.
Publicado: (2011)

PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.
por: Naylor, G. U., et al.
Publicado: (2022)

Male sterility in Mcl-1-flox mice is not due to enhanced Mcl1 protein stability
por: Ah-Cann, Casey, et al.
Publicado: (2016)

A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML
por: Wang, Qing, et al.
Publicado: (2019)

PB1759: RETAINED FUNCTIONAL NORMAL AND/OR PRE-LEUKEMIC HSCS IN THE BONE MARROW ARE ASSOCIATED TO GOOD PROGNOSIS IN DNMT3AMUTNPM1MUT AML PATIENTS
por: Donato, Elisa, et al.
Publicado: (2023)

MCL-1ES Induces MCL-1L-Dependent BAX- and BAK-Independent Mitochondrial Apoptosis
por: Kim, Jae-Hong, et al.
Publicado: (2013)

Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability
por: Tantawy, Shady I., et al.
Publicado: (2023)

P1350: M2-LIKE MONOCYTE-DERIVED MACROPHAGES PROTECT AML CELL LINES AND PRIMARY AML CELLS AGAINST THERAPY-INDUCED APOPTOSIS
por: Miari, Katerina, et al.
Publicado: (2023)

PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML
por: Kelekci, Simge, et al.
Publicado: (2023)

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax
por: Kour, Smit, et al.
Publicado: (2019)

Mcl-1 and tumor cell persistence
por: Pfannenstiel, Lukas W., et al.
Publicado: (2014)

MCL-1 inhibition in cancer treatment
por: Xiang, Weiguo, et al.
Publicado: (2018)

MCL1 as putative target in pancreatoblastoma
por: Reissig, Timm M., et al.
Publicado: (2022)

PB1800: CLINICAL CHARACTERISTICS AND MUTATION LANDSCAPE OF TRISOMY AML
por: Lam, Stephen S Y, et al.
Publicado: (2023)

PB1836: LOSS OF HETEROZYGOSITY IN AML PATIENTS WITH INV(16)
por: Bessmertniy, Dmitry, et al.
Publicado: (2023)

Nicotine Upregulates the Level of Mcl-1 through STAT3 in H1299 Cells
por: Zhou, Maojun, et al.
Publicado: (2020)

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
por: Prutsch, Nicole, et al.
Publicado: (2018)

Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines
por: Eichhorn, J M, et al.
Publicado: (2013)

Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner
por: Varadarajan, Shankar, et al.
Publicado: (2015)

PB1797: THE PROGNOSTIC SIGNIFICANCE OF BCAT1 ON NPM1+FLT3-ITD+ AML PATIENTS AND RELATED MOLECULAR MECHANISMS
por: Pan, Xinan, et al.
Publicado: (2023)

Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
por: Lemke, J, et al.
Publicado: (2014)

PB1764: SEGMENTATION AND CLASSIFICATION OF BONE MARROW CELLS FROM MULTI-PRECISION NUMERIZATION OF BONE MARROW SMEARS (BMS) FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) USING AI TECHNIQUES
por: Bennis, Achraf, et al.
Publicado: (2023)

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
por: Ewald, Larissa, et al.
Publicado: (2019)

2475 The leveling of clinical research competencies
por: Jones, Carolynn T., et al.
Publicado: (2018)

Regulation of Neutrophil Survival/Apoptosis by Mcl-1
por: Milot, Eric, et al.
Publicado: (2011)

Allosteric Inhibition of Anti-Apoptotic MCL-1
por: Lee, Susan, et al.
Publicado: (2016)

Targeting Mcl-1 for Radiosensitization of Pancreatic Cancers()()
por: Wei, Dongping, et al.
Publicado: (2015)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS
por: Stevens, Brett, et al.
Publicado: (2023)

Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma
por: Tong, Zhimin, et al.
Publicado: (2019)

Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
por: Prutsch, Nicole, et al.
Publicado: (2020)

Outcomes Following ACL and Grade III MCL Injuries: Is there a Role for MCL Repair?
por: Westermann, Robert W., et al.
Publicado: (2017)

PorthoMCL: Parallel orthology prediction using MCL for the realm of massive genome availability
por: Tabari, Ehsan, et al.
Publicado: (2017)

PB1783: IDENTIFICATION OF RAMAN SPECTROSCOPIC SIGNATURE OF IDH MUTATIONS IN AML IN VITRO MODEL
por: Laskowska, P., et al.
Publicado: (2022)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

PB1896: ACUTE MYELOID LEUKEMIA (AML): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cj8bnb0vj102ldkrbkg068nq7t